Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of recurrent bladder cancer after surgery for ureteral urothelial carcinoma
ChiCTR2400085287Phase 4Recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of bcg vaccine in ureteral urothelial carcinoma and bladder cancer (3 arms), sponsored by First Hospital of China Medical University. Primary endpoints: Recurrence rate of bladder tumor, Recurrence time of bladder tumor and 5 more. Started Jun 2024; status: recruiting.
02
Drugs
bcg vaccine
03
Conditions
ureteral urothelial carcinomabladder cancer
Beyond the preview
Go deeper on ChiCTR2400085287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085287.